

somapacitan (Sogroya®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2629	<p>for the replacement of endogenous growth hormone (GH) in children aged 3 years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric GHD), and in adults with growth hormone deficiency (adult GHD).</p> <p>SMC restriction: for children aged 3 years and above and adolescents with growth failure due to growth hormone deficiency (paediatric GHD).</p>	Not routinely available as the ADTC is waiting for further advice from local clinical experts	11/11/2024	03/01/2025
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/8726/somapacitan-sogroya-abbreviated-final-oct-2024-for-website.pdf				

linzagolix (Yselyt®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2631	<p>the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.</p> <p>SMC restriction: for use in patients when conventional first-line treatments (such as tranexamic acid, hormonal contraceptives and intrauterine devices) have failed or are considered unsuitable.</p>	Not routinely available as the ADTC is waiting for further advice from local clinical experts	11/11/2024	03/01/2025
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/8732/linzagolix-yselyt-final-april-2024-issued-oct-2024-for-website.pdf				
pembrolizumab (Keytruda®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2688	in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment, for the treatment of resectable non-small cell lung carcinoma at high risk of recurrence in adults.	Not routinely available as not recommended for use in NHS Scotland	18/11/2024	16/10/2024
Other Decision Specified : Economic analysis.				
Web Link : https://scottishmedicines.org.uk/media/8733/pembrolizumab-keytruda-final-oct-2024-for-website.pdf				

axicabtagene cilocleucel (Yescarta®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2695	for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	11/11/2024	03/01/2025
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/8728/axicabtagene-yescarta-resubmission-final-oct-2024-for-website.pdf				
tenecteplase (Metalyse®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2697	in adults for the thrombolytic treatment of acute ischaemic stroke within 4.5 hours from last known well and after exclusion of intracranial haemorrhage.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	11/11/2024	03/01/2025
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/8727/tenecteplase-metalyse-abbreviated-final-oct-2024-for-website.pdf				

quizartinib (Vanflyta®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2699	in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by quizartinib single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) that is FLT3-ITD positive.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	11/11/2024	03/01/2025
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/8725/quizartinib-vanflyta-final-oct-2024-for-website.pdf				
bismuth subcitrate potassium/ metronidazole/ tetracycline (Pylera®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2701	In combination with omeprazole, for the eradication of Helicobacter pylori and prevention of relapse of peptic ulcers in patients with active or a history of H. pylori associated ulcers. SMC restriction: restricted to use in accordance with clinical guidelines for the eradication of H. pylori	Not routinely available as the ADTC is waiting for further advice from local clinical experts	11/11/2024	03/01/2025
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/8729/bismuth-subcitrate-pylera-abbreviated-final-oct-2024-for-website.pdf				

lebrikizumab (Ebglyss®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2707	<p>for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.</p> <p>SMC restriction: patients who have had an inadequate response to an existing systemic immunosuppressant such as ciclosporin, or in whom such treatment is considered unsuitable and where a biologic would otherwise be offered.</p>	Not routinely available as the ADTC is waiting for further advice from local clinical experts	11/11/2024	03/01/2025
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/8731/lebrikizumab-ebglyss-final-oct-2024-updated-161024-for-website.pdf				
enzalutamide (Xtandi®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2742	as monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with high-risk biochemical recurrent (BCR) non-metastatic hormone-sensitive prostate cancer (nmHSPC) who are unsuitable for salvage radiotherapy.	Not routinely available as not recommended for use in NHS Scotland	11/11/2024	16/10/2024
Other Decision Specified : Non-Submission.				
Web Link : https://scottishmedicines.org.uk/media/8730/enzalutamide-xtandi-non-sub-final-oct-2024-for-website.pdf				